

AMENDMENT

1-34 (canceled)

35. (previously presented) A pharmaceutical composition comprising a Vitamin D compound and a hormone product in a single unit dosage.

36. (previously presented) The pharmaceutical composition of claim 35 wherein said hormone is a progestin product.

37. (previously presented) The pharmaceutical composition of claim 36 wherein the Vitamin D compound is present at a dosage equivalent of from 0.0001 to 1.0 mg 1,25-dihydroxyvitamin D<sub>3</sub>/kg of body weight and wherein the progestin product is present at a dosage less than or equal to a dosage equivalent to 10.0 mg of norethindrone.

38. (previously presented) The pharmaceutical composition of claim 37 wherein the Vitamin D compound is present at a dosage equivalent of from 0.005 to 0.1 mg 1,25-dihydroxyvitamin D<sub>3</sub>/kg of body weight and wherein the progestin product is present at a dosage less than or equal to a dosage equivalent to 1.0 mg of norethindrone.

39. (previously presented) The pharmaceutical composition in claim 35 wherein said hormone product is selected from the group consisting of estrogens and progestins.

40. (withdrawn) The pharmaceutical composition in claim 35 wherein said hormone product comprises estrogen.

41. (withdrawn) The pharmaceutical composition of claim 40 wherein the Vitamin D compound is present at a dosage equivalent of from 0.0001 to 1.0 mg 1,25-dihydroxyvitamin D<sub>3</sub>/kg of body weight.

42. (withdrawn) The pharmaceutical composition of claim 41 wherein the Vitamin D compound is present at a dosage equivalent of from 0.005 to 0.1 mg 1,25-dihydroxyvitamin D<sub>3</sub>/kg of body weight.

43. (withdrawn) The composition of claim 36 wherein said progestin product is a derivative of 17-alpha-hydroxy-progesterone or 19-nortestosterone.

44. (withdrawn) The composition of claim 40 wherein such estrogen is conjugated equine estrogen.

45. (previously presented) A contraceptive regimen comprising compositions including a Vitamin D compound and a hormone product.

46. (previously presented) The regimen of claim 45 wherein said hormone product includes a progestin product.

47. (withdrawn) The regimen of claim 46 wherein said progestin product is a derivative of 17-alpha-hydroxy-progesterone or 19-nortestosterone.

48. (withdrawn) The regimen of claim 47 wherein said progestin is levonorgestrel.

49. (previously presented) The regimen of claim 46 including a composition wherein Vitamin D compound and said progestin are present in a single unit dosage.

50. (withdrawn) The regimen of claim 45 wherein said hormone product includes a estrogen product.

51. (withdrawn) The regimen of claim 50 including a composition wherein Vitamin D compound and said estrogen are present in a single unit dosage.

52. (withdrawn) The regimen of claim 50 further including a progestin.

53. (withdrawn) The regimen of claim 52 wherein said Vitamin D compound, said progestin and said estrogen are present in a single unit dosage.

54. (withdrawn) The regimen of claim 53 wherein said progestin is a derivative of 17-alpha-hydroxy-progesterone or 19-nortestosterone.

55. (currently amended) A hormone replacement therapy regimen for administration to a post-menopausal woman comprising a compositions including Vitamin D compound and a hormone progestin product wherein the Vitamin D compound is present at a dosage equivalent of from 0.0001 to 1.0 mg 1.25 dihydroxyvitamin D<sub>3</sub> per kg of body weight.

56. (currently amended) The regimen of claim 55 wherein said hormone product includes a progestin product the Vitamin D compound is present at a dosage equivalent of from 0.005 to 0.75 mg of 1.25 dihydroxyvitamin D<sub>3</sub> per kg of body weight.

57. (currently amended) The regimen of claim 56 55 wherein said progestin product is a derivative of 17-alpha-hydroxy-progesterone or 19-nortestosterone.

58. (currently amended) The regimen of claim 57 wherein said progestin is levonorgestrel.

59. (previously presented) The regimen of claim 56 including a composition wherein Vitamin D compound and said progestin are present in a single unit dosage.

60. (withdrawn) The regimen of claim 55 wherein said hormone product includes a estrogen product.

61. (withdrawn) The regimen of claim 60 including a composition wherein Vitamin D compound and said progestin are present in a single unit dosage.

62. (withdrawn) The regimen of claim 60 further including a progestin.

63. (withdrawn) The regimen of claim 62 wherein said Vitamin D compound, said progestin and said estrogen are present in a single unit dosage.

64. (withdrawn) The regimen of claim 63 wherein said progestin is a derivative of 17-alpha-hydroxy-progesterone or 19-nortestosterone.

65. (new) The regimen of claim 55 wherein said progestin product is a gonane.

66. (new) The regimen of claim 56 wherein the Vitamin D compound is administered at a dosage equivalent of from 0.05 to 0.5 mg 1.25 dihydroxyvitamin D<sub>3</sub> per kg of body weight.

67. (new) A hormone replacement therapy regimen for administration to a post-menopausal woman comprising a composition including Vitamin D compound and a progestin product wherein the Vitamin D compound is 1.25 dihydroxyvitamin D<sub>3</sub> administered at a dosage equivalent to 400 I.U.

68. (new) The regimen of claim 67 wherein the Vitamin D compound is 1.25 dihydroxyvitamin D<sub>3</sub> administered at a dosage equivalent to 2000 I.U.

69. (new) The regimen of claim 68 wherein the Vitamin D compound is 1.25 dihydroxyvitamin D<sub>3</sub> administered at a dosage equivalent to 4000 I.U.

70. (new) The regimen of claim 67 wherein said progestin product is a derivative of 17-alpha-hydroxy-progesterone or 19-nortestosterone.

71. (new) The regimen of claim 67 wherein said progestin product is a gonane.

72. (new) The regimen of claim 67 wherein said progestin is norgestrel.

73. (new) The regimen of claim 67 including a composition wherein Vitamin D compound and said progestin are present in a single unit dosage.